Prevymis (letermovir) - Merck (MSD)
INTEGRATIVE BIOINFORMATIC AND REAL-WORLD DATA ANALYSIS REVEAL MECHANISTIC ASSOCIATIONS BETWEEN LETERMOVIR PROPHYLAXIS AND EBV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EHA 2026) - May 12, 2026 - Abstract #EHA-1218; PS2411; Pres time: Jun 13, 2026; 06:45 PM - 07:45 PM; Location: Hall A; "Our integrative model facilitates early identification of patients at high risk of EBV reactivation, guiding monitoring and intervention strategies. . Flowchart of the study" 
Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Infectious Disease • Inflammation • EGFR • HER-2 • HIF1A • PACERR • PPARG • PTGS2 • STAT3
https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eha/temp/eha26_abstract/PS2411.pdf
 
Zhangjie Chen 1; Sisi Zhen 1; Xin Chen 1; Sizhou Feng1
 
May 12, 2026
 
Prev Next